With 77134.0 shares changed hands, the volume of the stock remained heavier than its average volume of 63660.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $9.21 whereas the lowest price it dropped to was $8.46. The 52-week range on NTHI shows that it touched its highest point at $25.00 and its lowest point at $3.20 during that stretch.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NTHI was down-trending over the past week, with a drop of -12.70%, but this was down by -7.52% over a month. Three-month performance dropped to -16.70% while six-month performance rose 98.41%.
Float and Shares Shorts:
At present, 19.47 million NTHI shares are outstanding with a float of 4.28 million shares on hand for trading. On 2025-12-31, short shares totaled 0.13 million, which was 54.0 higher than short shares on 1764288000. In addition to Dr. Thomas C. Chen M.D., Ph.D. as the firm’s Founder, Chief Medical Officer, Chief Scientific Officer & Vice Chairman, Mr. Keithly A. Garnett serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, NTHI reported revenue of $0.0 and operating income of -$6934647.0. The EBITDA in the recently reported quarter was -$7347635.0 and diluted EPS was -$0.45.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is -$0.37 and the low estimate is -$0.37. The average estimate for the next quarter is thus -$0.37.
